Net benefit regarding the risk for death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials; are there any drug differences?

ABSTRACT:

SUBMITTER: Patoulias D 

PROVIDER: S-EPMC9167318 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature